New nanoparticle treatment for peritoneal ovarian cancer
Official title: Nanoparticle formulation of Mediator kinase inhibitor for the treatment of peritoneal ovarian cancer
Funded at Senex Biotechnology, INC. · NIH-11066897 · Data updated 2026-11-12
This study is testing a new way to deliver a cancer-fighting drug directly into the abdomen to help treat metastatic ovarian cancer, aiming to make the treatment more effective for patients facing this tough condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Senex Biotechnology, INC. NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project start | December 13, 2024 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $400,000 |
| NIH project number | 1R41CA298223-01 |
| Project ID | NIH-11066897 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with metastatic ovarian cancer localized to the peritoneal cavity who have not responded adequately to conventional therapies.
✕Less likely to help
Patients with early-stage ovarian cancer or those whose cancer has metastasized beyond the peritoneal cavity may not benefit from this research.
What this research studies
This research focuses on developing a novel nanoparticle formulation of a Mediator kinase inhibitor to treat metastatic ovarian cancer, particularly in the peritoneal cavity. The approach aims to enhance the effectiveness of the drug SNX631-6 by delivering it directly into the abdominal cavity through intraperitoneal (IP) administration, which could improve its absorption and efficacy compared to oral delivery. The study investigates the drug's ability to inhibit tumor growth and aims to provide a more targeted treatment option for patients with this challenging cancer type.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for patients suffering from peritoneal ovarian cancer, potentially improving survival rates and quality of life.
How similar studies have gone: While the use of nanoparticle formulations in cancer treatment is a growing field, this specific approach targeting Mediator kinases in peritoneal ovarian cancer is novel and has not been extensively tested in prior studies.
Where this research is happening
-
Senex Biotechnology, INC.
Columbia, United States Active
Researchers
- Principal investigator: Chen, Mengqian — Senex Biotechnology, INC.
- Study coordinator: Chen, Mengqian
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.